Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Branka Cucevic"'
Autor:
Sonja Badovinac, Marta Korsic, Branka Cucevic, Valentina Slivnjak, Andrea Vukic Dugac, Marko Jakopovic
Publikováno v:
Jornal Brasileiro de Pneumologia, Vol 39, Iss 4, Pp 525-528 (2013)
Externí odkaz:
https://doaj.org/article/fd30fa7e359944f2a93a6c17264a3dcf
Autor:
Davorka Mursic, Miroslav Samarzija, Marta Korsic, Mihovil Roglić, Sonja Badovinac, Branka Cucevic, Marko Jakopović
Background: Lung cancer is the leading cause of cancer deaths and the non-small cell lung cancer (NSCLC) represents 80% of all cases. In most cases when diagnosed, it is in locally advanced or metastatic stage, when platinum based doublet chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdaa32676122892fb7ccac9292fa07e3
https://doi.org/10.21037/jtd.2016.05.56
https://doi.org/10.21037/jtd.2016.05.56
Autor:
Patrick Peterson, Tudor Ciuleanu, Jayaprakash Madhavan, Carla Visseren-Grul, Thomas Brodowicz, Maciej Krzakowski, Astra M. Liepa, Fabio Franke, Christoph C. Zielinski, Sung Hyun Yang, Armando Santoro, Branka Cucevic, William J. John, Chandra P. Belani, Rodryg Ramlau
Publikováno v:
The Lancet Oncology. 13:292-299
Summary Background Pemetrexed maintenance therapy significantly improved overall survival and progression-free survival compared with placebo, and had a good safety profile in a phase 3 placebo-controlled study in patients with advanced non-small-cel
Autor:
Christoph C. Zielinski, Maciej Krzakowski, Katherine P. Sugarman, Joo Hang Kim, Thomas Brodowicz, Sung Hyun Yang, Patrick Peterson, E. Laack, Isabel Bover, Chandra P. Belani, Yi-Long Wu, Stephen Begbie, Valentina Tzekova, K. Krejcy, Jayaprakash Madhavan, José Rodrigues Pereira, William J. John, Tudor Ciuleanu, Branka Cucevic
Publikováno v:
The Lancet. 374:1432-1440
Summary Background Several studies have shown the efficacy, tolerability, and ease of administration of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-cell lung cancer. We assessed pemetrexed as maintenance ther
Autor:
Mária Szilasi, Kalman Gyurkovits, Branka Cucevic, Christoph C. Zielinski, Mislav Grgic, Valentina Tzekova, Nicolae Ghilezan, Thomas Brodowicz, Pinar Saip, Ernst Ulsperger, Maciej Krzakowski, Miklos Wenczl, Tudor Ciuleanu, Jacek Jassem, Victoria Soldatenkova, Natalya Oskina, Maria Wagnerova, Matjaz Zwitter, Christoph Wiltschke, Rodryg Ramlau
Publikováno v:
Lung Cancer. 52:155-163
The primary objective of this randomized phase III study was to show significant difference in median time to progression (TTP) in patients with advanced NSCLC treated with single-agent gemcitabine maintenance therapy versus best supportive care foll
Autor:
Ivica Mazuranic, Sanja Pleština, Branka Cucevic, Gzim Redzepi, Lela Bitar, Andrea Vukić Dugac, Mateja Janković, Marko Jakopović, Sven Seiwerth, Ana Hećimović, Miroslav Samarzija
Publikováno v:
Journal of Clinical Oncology. 35:e20518-e20518
e20518 Background: EGFR T790M mutation is responsible for around 60% cases of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in patients who have lung cancer with an activating EGFR mutation. Methods: We admini
Autor:
Sven Seiwerth, Mihovil Roglić, Fran Seiwerth, Suazana Kukulj, Miroslav Samarzija, Marija Misic, Sanja Plestina, Gordana Bubanović, Branka Cucevic, Silvana Smojver-Jezek, Gordana Drpa, Luka Brcic, Marko Jakopović
Publikováno v:
Journal of Thoracic Oncology. 12:S517
Autor:
Sven Seiwerth, Gordana Drpa, Suzana Smojver-Ježek, Suzana Kukulj, Branka Cucevic, Marija Misic, Miroslav Samaržija, Sanja Pleština, Marko Jakopović, Luka Brcic, Mihovil Roglić, Fran Seiwerth
Publikováno v:
Journal of Clinical Oncology. 34:e23238-e23238
Rates in targetable gene changes varies between different populations of lung cancer patients. Targetable genes changes include changes in EGFR and ALK gene, as well as KRAS gene. Primary aim of this study was to determine mutation status in purely C
Autor:
Kalman Gyurkovits, Branka Cucevic, Ulsperger Ernst, Valentina Tzekova, Matjaz Zwitter, Thomas Brodowicz, Miklos Wenczl, Ghilezan N, Rodryg Ramlau, Maciel Krzakowski, Christoph C. Zielinski
Publikováno v:
Lung Cancer. 41:S29